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Abstract
Background: The cell cycle is promoted by activation of cyclin dependent kinases (Cdks), which
are regulated positively by cyclins and negatively by Cdk inhibitors. Proliferation of carcinoma is
associated with altered regulation of the cell cycle. Little is known on the combined alterations of
cyclins A, B1, D1 and E in breast cancer in relation to the tumour grade and other prognostic
factors.
Findings:  Immunohistochemical analysis of cyclins A, B1, D1 and E, estrogen receptor,
progesterone receptor, Ki-67, Her-2/neu and CK5/6 was performed on 53 breast carcinomas.
mRNA levels of the cyclins were analysed of 12 samples by RT-PCR. The expression of cyclins A,
B1 and E correlated with each other, while cyclin D1 correlated with none of these cyclins. Cyclins
A, B1 and E showed association with tumour grade, Her-2/neu and Ki-67. Cyclin E had a negative
correlation with hormone receptors and a positive correlation with triple negative carcinomas.
Cyclin D1 had a positive correlation with ER, PR and non-basal breast carcinomas.
Conclusion:  Cyclin A, B1 and E overexpression correlates to grade, Ki-67 and Her2/neu
expression. Overexpression of cyclin D1 has a positive correlation with receptor status and non-
basal carcinomas suggesting that cyclin D1 expression might be a marker of good prognosis.
Combined analysis of cyclins indicates that cyclin A, B and E expression is similarly regulated, while
other factors regulate cyclin D1 expression. The results suggest that the combined
immunoreactivity of cyclins A, B1, D and E might be a useful prognostic factor in breast cancer.
Introduction
Breast cancer includes a heterogeneous group of tumours
with variable prognosis and is a leading cause of death in
women [1]. Tumour grade and size, hormone receptor
status, lymph node status, and age are traditionally related
to breast cancer prognosis [2]. A key event in tumorigene-
sis is the alteration of the genetic material, which modifies
the expression of proteins in cell cycle progression [3]. The
cell cycle is promoted by activation of cyclin dependent
kinases, which are positively regulated by cyclins and neg-
atively by Cdk inhibitors. This tightly controlled expres-
sion is altered in tumour cells [4]. In breast cancer,
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overexpression of cyclins A and E has been associated with
poor prognosis [5,6] and cyclin B1 with tumour grade, Ki-
67, mitoses and adverse clinical outcome [7]. The role of
cyclin D1 in breast cancer remains unclear showing vary-
ing correlation to prognosis [8].
Recent gene expression studies have characterized five dis-
tinct breast carcinoma classes, two of them are ER positive
(luminal A and B) and three ER negative (Her2/neu-over-
expressing, normal breast-like and basal-like types) [9-
11]. Basal-like cancers are positive for basal cytokeratins,
but negative for hormone receptors and Her-2/neu and
have been reported to be associated with worse prognosis
[10]. This basal-like subgroup (ER-, PR-, Her-2/neu-, CK5/
6+) includes basal cytokeratin negative tumours, which
are called triple negative carcinomas (ER-, PR-, Her-2/neu-
).
Although many studies have evaluated the expression and
prognostic role of individual cyclins in breast cancer, little
is known of their combined expression with traditional
prognostic factors. Here, we have immunohistochemi-
cally evaluated cyclin A, B1, D1 and E expression in 53
breast cancers, correlated the results with grade and other
prognostic factors as well as with triple negative and basal-
like breast carcinomas. In addition, we analysed a subset
of samples at the mRNA level to see whether the transcrip-
tional level of cyclins correlates with the immunohisto-
chemical results.
Materials and methods
Patient and tissue material, immunohistochemistry, HER-
2/neu chromogen in situ hybridisation, real-time quanti-
tative polymerase chain reaction and statistical analyses
are provided in additional file 1. The clinical characteristic
of the patients are described in Table 1.
Results
The immunohistochemical staining of cyclins A, B1, D1
and E was successful in all 53 breast cancers. Representa-
tive results for each cyclin staining are presented in Figure
1. The cyclin A expression ranged from 0% to 59% in
tumour samples (Figure 2). Cyclin B1 expression was low
as compared to cyclin A expression and ranged from 0%
to 30%. The expression of cyclin E ranged from 1% to
76% and the expression of cyclin D1 ranged between 3–
90%. A significant positive correlation was seen between
grade and Ki-67 (r = 0.62, p < 0.0001), and Her-2/neu
immunohistochemistry (r = 0.35, p = 0.0104).
The immunohistochemically detected expression of cyclin
A (p = 0.0011), B1 (p = 0.0047) and E (p = 0.0005)
showed significant associations with tumour grade (Fig-
ure 3). In addition, cyclin A, B1 and E expression showed
positive correlation with Ki-67 expression (r = 0.71, p <
0.0001 for cyclin A, r = 0.57, p < 0.0001 for cyclin B1 and
r = 0.60, p < 0.0001 for cyclin E), while cyclin D1 staining
showed no significant correlation with grade or Ki-67
expression. None of the cyclins showed correlation with
tumour size or metastases.
Cyclin A (r = 0.32, p = 0.0264), cyclin B1 (r = 0.43, p =
0.0026) and cyclin E staining (r = 0.34, p = 0.0199) had a
significant positive correlation with Her-2/neu expres-
sion, while cyclin D1 staining did not have any correla-
tion with Her-2/neu expression. The tumour grade had
also a significant positive correlation with Her-2/neu
expression (r = 0.46, p = 0.0011). Cyclin D1 staining had
a significant positive correlation with expression of ER (r
= 0.37, p = 0.0088) and PR (r = 0.33, p = 0.0233) whereas
cyclin E staining had a significant negative correlation
with ER (r = -0.37, p = 0.0100) and PR status (r = -0.35, p
= 0.0153). Cyclins A and B1 did not show any correlations
with ER or PR status.
Cyclin A, B1 and E expression correlated with each other,
but not with cyclin D1. Cyclin A had a significant positive
correlation with cyclin E (r = 0.49, p = 0.0004) and espe-
cially with cyclin B1 (r = 0.60, p < 0.0001). On the other
hand, cyclin B1 had a significant positive correlation with
cyclin E (r = 0.52, p = 0.0001). High cyclin E expression
correlated with triple negative cancers (p = 0.0474), while
cyclin D1 expression correlated with non-triple negative
carcinomas (p = 0.0156) and non-basal-like carcinomas
(p = 0.0279). Cyclins A and B1 didn't show any correla-
tion with triple negative or basal-like breast carcinomas.
Nor showed cyclin E any correlation with basal-like carci-
nomas.
The mRNA expression of the four cyclins was analyzed by
RT-PCR in 12 breast cancer samples (Figure 4). Cyclin A
gene expression was increased in 9/12 tumours, cyclin B1
in 9/12 tumours, cyclin D1 in 7/12 tumours and cyclin E
in all 12 tumours. Although differences were seen
between the gene expressions, a number of similarities
were also observed, for example higher expression of cyc-
lins A, B1 and E in ductal carcinoma grade III tumours.
Also, two ductal carcinomas in situ GIII had higher cyclin
A gene expression than other breast tumours (however,
third DCIS GIII had lower gene expression than normal
breast tissue). Ductal carcinoma in situ GIII patients had
also a moderate gene expression for cyclin B1 and E. In
our material, cyclin D1 gene expression was variable.
Comparisons between the immunohistochemical expres-
sion of different cyclins and quantitative PCR demon-
strated disagreement in certain tumours. Further
assessment of the statistical correlations between the gene
expression and immunohistochemical expression were
not possible due to the relatively limited number of sam-
ples.BMC Research Notes 2009, 2:140 http://www.biomedcentral.com/1756-0500/2/140
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Table 1: Patients and tumour characteristics
Variable Number of patients (%)
Number of the patients
Grade
53 (aged 40–94, mean 67)
I 7 (13.2%)
II 24 (45.3%)
III 18 (34%)
in situ II 1 (1.9%)
in situ III 3 (5.7%)
Axillary nodal status
N0 25 (47.2%)
N1–3 12 (22.6%)
N4–9 11 (20.8%)
>N10 3 (5.7%)
Unknown (axillary evacuation done 1993 and 1994) 2 (3.8%)
Tumour size
≤ 2 cm 13 (24.5%)
> 2 cm 40 (75.5%)
Estrogen receptor status (ER)1)
Positive 35 (66%)
Negative 14 (26.4%)
Positive in DCI 3 (5.7%)
Negative in DCIS 1 (1.9%)
Progesterone receptor status (PR)1)
Positive 36 (68%)
Negative 13 (24.5%)
Positive in DCIS 3 (5.7%)
Negative in DCIS 1 (1.9%)
Ki-67 status
<5% 7 (13.2%)
5–19% 16 (30.2%)
20–29% 8 (15.1%)
>20% 22 (41.5%)
Histologic type
Ductal 37 (69.8%)
Lobular 8 (15.1%)
Subtypes 4 (7.5%)
Ductal carcinoma in situ 4 (7.5%)
Her-22)
IHC positive (2+ and 3+) 20 (37.7%)
IHC negative (0 and 1+) 29 (54.7%)
IHC positive in DCIS 2 (3.8%)
IHC negative in DCIS 2 (3.8%)
CISH positive 10 (18.9%)
CISH positive in DCIS 2 (3.8%)
CK 5/63)
Triple-negative (ER-, PR-, Her-2/neu-) 11 (20.8%)
Basal-like carcinoma (ER-, PR-, Her-2/neu-, CK5/6+) 8 (15.1%)
1,3) Cut off point used for ER and PR immunohistochemistry is 10% of positively stained tumour cell nuclei and 10% cytoplasmic staining for CK5/6.
2) All IHC Her 2+ and 3+ cases were retested by CISH. Scoring of HER2/neu immunohistochemistry: Score 0: no staining is observed or cell 
membrane staining is observed in less than 10% of tumour cells. Score 1+: a faint perceptible membrane staining can be detected in more than 10% 
of the tumour cells or cells are only stained in part of their membrane. Score 2+: a weak to moderate complete membrane staining is observed in 
more than 10% of the tumour cells. Score 3+: a strong complete membrane staining is observed in more than 10% of the tumour cells.BMC Research Notes 2009, 2:140 http://www.biomedcentral.com/1756-0500/2/140
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Discussion
To our knowledge this is the first study, where the expres-
sion of cyclins A, B1, D1 and E is collectively analysed in
breast cancer to determine the correlation with tumour
grade and other traditional prognostic factors as well as
with basal-like (ER-, PR- and Her-2/neu-, CK5/6+) and tri-
ple negative breast carcinomas (ER-, PR- and Her-2/neu-,
CK5/6-). Overexpression of cyclins A, B1, and E has been
reported to associate with poor prognosis in breast cancer
[5-7]. Therefore, it was not surprising that the immunore-
activity of cyclins A, B1 and E showed significant associa-
tion with tumour grade, Her-2/neu and Ki-67 expression.
Immunohistochemically detected expression of cyclins A,
B1 and E correlated with each other, but not with cyclin
D1. Furthermore, cyclin E had a negative correlation with
hormone receptor status and a positive correlation with
triple negative breast carcinomas associating cyclin E
expression with unfavourable prognosis. The role of cyc-
lin D1 as a marker of breast cancer prognosis is somewhat
speculative and contradictory results have been published
[8]. Nevertheless, we observed a significant positive corre-
lation between immunoreactivity of cyclin D1 and hor-
mone receptors as well as with non-basal-like carcinomas
and non-triple negative carcinomas. In addition, cyclin
D1 did not correlate with grade, Ki-67, Her-2/neu suggest-
ing that increased cyclin D1 level might be a marker of
good outcome.
In breast cancer, high cyclin A expression has been dem-
onstrated to correlate with tumour grade, Ki-67 and Her-
Immunohistochemical staining of cyclins A, B1, D1 and E in infiltrating ductal carcinoma GIII Figure 1
Immunohistochemical staining of cyclins A, B1, D1 and E in infiltrating ductal carcinoma GIII. All stainings are 
from the same tumour.BMC Research Notes 2009, 2:140 http://www.biomedcentral.com/1756-0500/2/140
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2/neu [5]. Our findings are in agreement with these obser-
vations. On the other hand, although cyclin A correlated
with poor prognosis, it was unexpected to find that nei-
ther cyclin A, nor any of the other cyclins studied showed
correlation with tumour metastasis. There are, however,
also opposite results concerning the roles of cyclin A as a
prognostic marker. Kuhling and co-workers (2003)
reported that cyclin A did not achieve statistical signifi-
cance in predicting disease-specific and metastasis-free
survival [12]. These contradicting results may be, at least
partly, explained by the fact that tumours with high pro-
liferation rate and cyclin A expression may have a more
favourable response to chemotherapy [13].
We analysed a subset of samples to study whether the
transcription of cyclin mRNAs correlate with the cyclin
protein levels using quantitative PCR, which is a precise
method to determine the amount of mRNA. Our results
demonstrated increased transcription of cyclins in most of
the tumour samples analysed. When the mRNA levels
were compared with the protein levels, many similarities
were observed, although some differences also were evi-
dent. An example of this is cyclin B1, where the gene
expression was up-regulated in 9/12 cases (75%) and the
mRNA levels tended to be high in grade III tumours. Fur-
thermore, immunohistochemically detected expression of
cyclin B1 showed a significant association with tumour
grade, Ki-67 and Her-2/neu as well as with cyclin E expres-
sion. Others have also found an association between cyc-
lin B1 overexpression and poorer survival in breast cancer
[14].
Despite several studies, the exact role of cyclin D1 in
breast cancer remains unclear. The expression of cyclin D1
has previously been shown to positively correlate with ER
status and negatively with tumour grade and size, thus
suggesting that cyclin D1 overexpression is a marker of
good outcome particularly when ER is coexpressed [15].
Our findings in the present study go along with these
observations. There are also reports showing that overex-
A scattergram showing positive immunohistochemical cyclin expression (%) with mean values of cyclins A, B1, E and D1 in all  tumours (n = 53) Figure 2
A scattergram showing positive immunohistochemical cyclin expression (%) with mean values of cyclins A, B1, 
E and D1 in all tumours (n = 53). The different characters depict individual tumours.BMC Research Notes 2009, 2:140 http://www.biomedcentral.com/1756-0500/2/140
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pression of cyclin D1 predicts tamoxifen treatment resist-
ance in breast cancer patients [16-19] and associates with
poor prognostic features in estrogen receptor positive
breast cancer [8]. Furthermore, cyclin D1 is thought to
mediate cell proliferation by different mechanisms in
estrogen receptor positive and negative breast cancer [8].
In our RT-PCR study, cyclin D1 gene was up-regulated in
7/12 (58%) tumours studied, which is higher than previ-
ously reported (5–20%) [20]. When cyclin D1 mRNA
level was compared with the immunohistochemically
detected expression, cyclin D1 immunoreactivity was con-
stantly higher suggesting that translation of cyclin D1 is
not always secondary to gene transcription and other
mechanisms as defects in the proteasomal degradation of
cyclin D1 [21] may affect the maintenance of cyclin D1
overexpression.
Several studies have shown that cyclin E immunoreactiv-
ity correlates with negative ER status, higher tumour
grade, HER-2/neu and higher proliferation index [22].
Our findings in the present study are in agreement with
these observations, as immunohistochemically detected
expression of cyclin E showed significant association with
histological grade, Ki-67, Her-2/neu staining and a nega-
tive correlation with ER and PR status. We also observed a
positive correlation between cyclin E immunoreactivity
and triple negative carcinomas. Furthermore, compared
to normal breast tissue, cyclin E mRNA expression was up-
regulated in all 12 samples analysed by quantitative PCR.
Previous studies have demonstrated some differences
between quantitative PCR results and immunohistochem-
ically detected expression of cyclin E [23]. This discrep-
ancy may be explained by the fact that mRNA used for
PCR originated from cancer cells as well as from tumour
The association of histological grade of the breast cancer with the immunohistochemical expression of cyclin A, B1, E and D1 Figure 3
The association of histological grade of the breast cancer with the immunohistochemical expression of cyclin 
A, B1, E and D1. P-values for cyclin A: overall p = 0.0025, grade I vs II p = 0.3774, grade I vs III p = 0.0069, grade II vs III p = 
0.0321. P-values for cyclin B1: overall p = 0.0058, grade I vs II p = 0.5466, grade I vs III p = 0.015, gradus II vs III p = 0.048. P-
values for cyclin E: overall p < 0.0001, grade I vs II p = 0.294, grade I vs III p = 0.0063, grade II vs III p < 0.0003. Cyclin D1 did 
not show any correlation with the grades.BMC Research Notes 2009, 2:140 http://www.biomedcentral.com/1756-0500/2/140
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stromal cells, while in immunohistochemical staining
only cancer cells are scored [23]. However, in our study
cyclin E immunoreactivity seemed to reflect the amount
of cyclin E mRNA detected by quantitative PCR, as the
highest mRNA levels were detected in grade III samples.
Conclusion
This study shows that the aggressive breast cancers overex-
press cyclins A, B1 and E whereas cyclin D1 expression is
independent of the other cyclins. The overexpression of
cyclin D1 has a significant positive correlation with hor-
mone receptor status, non-triple negative and non-basal-
like breast carcinomas suggesting that cyclin D1 expres-
sion might be a marker of good prognosis. Despite of the
small number and heterogeneity of the our patient mate-
rial it may be beneficial to study the expression of cyclins
A, B1, D1 and E together with other cell cycle regulators,
when determining breast cancer prognosis.
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